Share information
The shares of Biotec Pharmacon ASA are listed on the Oslo Stock Exchange. The listing took place on 4 November 2005.
 |
The ticker symbol for Biotec Pharmacon is BIOTEC. Click here for share price information from the Oslo Stock Exchange.
Biotec Pharmacon has 23,637,910 shares outstanding with a nominal value of NOK 1 per share. Click here for an overview of the main shareholders.
The share registrar is
Fokus Bank, Verdipapirservice, P.O. Box 1171 Sentrum, 0107Oslo, Norway.
For Investor Relations inquiries, please contact CFO Jørn Lunde, Drammensveien 149, 0277 Oslo, telephone +4777648900.
Click herefor inquiries by e-mail.
News
- Svein Lien appointed new CEO of Biotec Pharmacon ASAMarch 10,2010Svein Lien has been appointed new CEO of Biotec Pharmacon, following Lars Viksmoen’s decision to resign after 3 years as CEO. Svein Lien will assume the position with effect from 15 March, 2010.
- Biotec Pharmacon presenting re-established platform at BIO-Europe 2010March 09,2010Dr Sven Rohmann presented on behalf of Biotec Pharmacon at BIO-Europe Spring 2010 in Barcelona. The presentation took place at March 9, 12:30, under the AutoImmune/Inflammation Section.
- Testing SBG packaging containers after weak results from oral mucositis study February 22,2010Biotec Pharmacon has received data showing that SBG failed to show superiority over placebo in the phase III study for oral mucositis. Newly available biological activity assays indicate that SBG used in the diabetic ulcer program may have been inactivated as a result of interaction with polyethylene in the product containers. The company plans to carry out accelerated stability studies of SBG with alternative containers.